OpGen, Inc. (OPGN), a leading precision medicine company specializing in molecular diagnostics and bioinformatics for combatting infectious diseases, experienced an impressive surge in after-market trading on Thursday.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock price soared to $0.7710, reflecting a substantial increase of 24.35%, without any specific catalyst identified.
Q1 2023 Financial Results Demonstrate Strong Growth
OpGen recently released its financial and operating results for the first quarter of 2023, revealing a robust performance and noteworthy revenue growth. The following key highlights underscore the company’s progress:
Impressive Revenue Growth
OpGen recorded approximately $0.91 million in total revenue for Q1 2023, marking an impressive 94% increase compared to the $0.47 million generated in Q1 2022. This remarkable growth showcases OpGen’s ability to seize market opportunities effectively. Furthermore, the company’s revenue grew by 26% compared to the previous quarter, indicating a positive growth trajectory.
Effective Expense Management
OpGen managed to reduce its total operating expenses to $6.0 million for Q1 2023, down from $6.3 million in the corresponding quarter of the previous year. This reduction highlights OpGen’s commitment to optimizing operational efficiency and cost control.
Stable Financial Position
As of March 31, 2023, OpGen maintained a strong financial position with approximately $7.0 million in cash and cash equivalents. While there was a slight decrease from $7.4 million as of December 31, 2022, the company’s solid cash reserves provide a robust foundation for ongoing operations and future growth initiatives.
Key Milestones and Collaborations
OpGen achieved significant milestones during the period, positioning itself for future success. Notable accomplishments include:
Successful Curetis Collaboration
OpGen’s subsidiary, Curetis, successfully completed all remaining key milestones in its research and development collaboration project with the Foundation for Innovative New Diagnostics (FIND). Additionally, Curetis expanded its collaboration with FIND by adding three work packages, increasing the project’s total volume to approximately $913 thousand in revenue.
FDA Submission
OpGen submitted a De Novo classification request to the U.S. Food and Drug Administration (FDA) for the marketing authorization of the Unyvero Urinary Tract Infection (UTI) panel. The FDA confirmed the submission’s completeness and initiated substantive review. If approved, the Unyvero UTI panel would become the first-ever rapid multiplex sample-to-answer in vitro diagnostic test for urinary tract infections available in the United States, presenting significant market potential.
Strategic Distribution Agreement
OpGen entered into a non-exclusive distribution agreement with Fisher Healthcare, a division of Thermo Fisher Scientific. This strategic partnership aims to distribute the Unyvero A50 platform and in vitro diagnostic tests for pneumonia and urinary tract infections, expanding OpGen’s market reach.
Future Outlook and Investment Considerations
OpGen maintains its guidance for 2023, affirming its commitment to pursuing substantial revenue growth opportunities. The company projects global revenues from its products, services, and collaborations to range from approximately $4 to $5 million. OpGen also intends to actively engage in interactive reviews with the FDA regarding the clearance decision for the De Novo classification request for the Unyvero UTI panel. These developments position OpGen favorably for future success and present investors with a promising investment opportunity in the precision medicine and infectious disease diagnostics sector.
